Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis

Lamoth, Frederic, Nucci, Marcio, Fernandez-Cruz, Ana, Azoulay, Elie, Lanternier, Fanny, Bremerich, Jens, Einsele, Hermann, Johnson, Elizabeth, Lehrnbecher, Thomas, Mercier, Toine, Porto, Luciana, Verweij, Paul E, White, Lewis, Maertens, Johan, Alanio, Alexandre, Aerts, Robina, Akova, Murat, Alanio, Alexandre, Averbuch, Diana, Blennow, Ola, Bretagne, Stéphane, Busca, Alessandro, Calandra, Thierry, Cesaro, Simone, Cordonnier, Catherine, De La Camara, Rafael, Garcia-Vidal, Caroline, Gil, Lidia, Groll, Andreas, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Peter, Indolfi, Giuseppe, Kassa, Csaba, Lagrou, Katrien, Lamoth, Frederic, Lehrnbecher, Thomas, Ljungman, Per, Maertens, Johan, Mallet, Vincent, Martino, Rodrigo, Mehra, Varun, Mercier, Toine, Mikulska, Malgorzata, Nucci, Marcio, Pagano, Livio, Perruccio, Katia, PiÑana, Jose Luis, Porto, Luciana, Robin, Christine, Roilides, Emmanuel, Slavin, Monica, Styczynski, Jan, Tverdek, Frank, Verweij, Paul, Vissing, Nadja Hawwa, White, Lewis, Xhaard, Alienor and Spychala, Olga Zajac 2023. Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis. Medical Mycology 61 (7) , myad061. 10.1093/mmy/myad061

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (736kB) | Preview

Abstract

The (1→3)-β-D-glucan (BDG) is a component of the fungal cell wall that can be detected in serum and used as an adjunctive tool for the diagnosis of invasive mold infections (IMI) in patients with hematologic cancer or other immunosuppressive conditions. However, its use is limited by modest sensitivity/specificity, inability to differentiate between fungal pathogens, and lack of detection of mucormycosis. Data about BDG performance for other relevant IMI, such as invasive fusariosis (IF) and invasive scedosporiosis/lomentosporiosis (IS) are scarce. The objective of this study was to assess the sensitivity of BDG for the diagnosis of IF and IS through systematic literature review and meta-analysis. Immunosuppressed patients diagnosed with proven or probable IF and IS, with interpretable BDG data were eligible. A total of 73 IF and 27 IS cases were included. The sensitivity of BDG for IF and IS diagnosis was 76.7% and 81.5%, respectively. In comparison, the sensitivity of serum galactomannan for IF was 27%. Importantly, BDG positivity preceded the diagnosis by conventional methods (culture or histopathology) in 73% and 94% of IF and IS cases, respectively. Specificity was not assessed because of lacking data. In conclusion, BDG testing may be useful in patients with suspected IF or IS. Combining BDG and galactomannan testing may also help differentiating between the different types of IMI.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Centre for Trials Research (CNTRR) Medicine
Publisher:	Informa Plc.
ISSN:	1369-3786
Date of First Compliant Deposit:	27 March 2024
Date of Acceptance:	26 June 2023
Last Modified:	05 Apr 2024 13:26
URI:	https://orca.cardiff.ac.uk/id/eprint/167590

Actions (repository staff only)

Edit Item